Form 4 for AKBA Akebia Therapeutics, Inc.

Accepted 2023-02-02 00:00:00 ET · period of report 2023-01-31 · accession 0001562180-23-000830 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-02-02	2023-01-31	AKBA	Burke Steven Keith	SVP, Chief Medical Off	A - Grant	$0.00	+196.2K	615.7K	+47%	$0
D	2023-02-02	2023-01-31	AKBA	Burke Steven Keith	SVP, Chief Medical Off	A - Grant	$0.00	+294.3K	294.3K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-01-31	A	A	196,200	$0.00	615,716	D	—	—	(F1) The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. (F2) Includes 1,500 shares of the Issuer's common stock purchased on December 30, 2022 under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan.
2	Derivative	Stock Option (Right to buy)	2023-01-31	A	A	294,300	$0.00	294,300	D	$0.63 · — to 2033-01-31	294,300 Common Stock	(F3) The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.